Patent ID: 8318166
Filing Date: 2012-11-27
Classification: A61K,A61P,C07K

Abstract:
1. A method for treating hematologic malignancies comprising the step of administering to a patient an effective amount of a ligand of HVEM, wherein said ligand of HVEM is a monoclonal antibody selected from the group consisting of: (i) a monoclonal antibody that does not bind to an HVEM mutant in which cysteine rich domain 1 (CRD1) of HVEM is deleted (CRD1 deletion mutant) but is affected by an HVEM mutant in which amino acid residues 129-133 within cysteine rich domain 3 of HVEM have been deleted (del129-133 deletion mutant) and blocks the binding of HVEM to LIGHT, not the binding of HVEM to BTLA or HSV-gD; (ii) a monoclonal antibody that that does bind to an CDR (iii) a monoclonal antibody that does not bind to the CRD1 deletion mutant and is not affected by the del129-133deletion mutant , and does not inhibit the binding of HVEM to LIGHT, BTLA or HSV-gD; (iv) a monoclonal antibody that is not affected by the CRD (v) a monoclonal antibody that does bind to the CRD1 deletion but not to the del129-133 deletion mutant, is not affected by the mut131-133 mutant, and is not able to block HVEM binding to LIGHT, BTLA or HSV-gD; and (vi) a monoclonal antibody that does bind to the CRD1 deletion mutant but is affected in part by the del129-133deletion mutant, or by the mut131-133 mutant, and is able to block HVEM binding to LIGHT, BTLA and HSV-gD, and said monoclonal antibody induces apoptosis in a malignant lymphocyte.